Meet the Johnson & Johnson Innovation Team
MaRS Auditorium, Lower Concourse , MaRs Centre , Toronto , ON M5G 1L7
October 29, 2015 from 15:00 PM to 17:00 PM (EDT)
$10 - $35
Johnson & Johnson Innovation recently announced the opening of JLABS @ Toronto, a partnership with University of Toronto, the Ontario Government and the MaRS Discovery District. Now is your chance to meet the team charged with a new kind of partnering program! Don't miss this opportunity to learn more on the progress of this ground-breaking project. Join us for a chance to be one of the first to hear from Johnson & Johnson Innovation in person.
Over the past few years, Innovators around the US have gotten a chance to know us at JLABS and that has given us an opportunity to interact with you and to think about what else you, the Innovator, need to get your science to the patient. Through our engagement, we continue to evolve in an effort to better meet the needs of the Innovator and ultimately the patient. It is because of you that Johnson & Johnson Innovation (J&J Innovation) created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The J&J Innovation team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
Together our teams can provide you the best possible chance of taking your solution to the people who need it the most.
On October 29, hear from Johnson & Johnson Innovation leaders Kuldeep Neote, Senior Director of New Ventures, Tom Luby, Senior Director of New Ventures, Bruce Rosengard, the Chief Medical Science and Technology Officer for J&J Medical Devices Companies, and Melinda Richter, Head of JLABS. Kuldeep, Tom, Bruce, and Melinda will provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives. Don't miss this opportunity to learn more on the progress of this ground-breaking project. Join us for a chance to be one of the first to hear from the Johnson & Johnson Innovation Center in person.
2:00pm | Registration opens, Networking
2:30pm | Presentation and Q&A
4:00pm | Program closes
Johnson & Johnson Participating Representatives:
Kuldeep Neote | Senior Director, New Ventures, J&J Innovation read bio»
Tom Luby | Senior Director, New Ventures, J&J Innovation read bio»
Melinda Richter | Head, J&J Innovation, JLABS read bio»
Bruce Rosengard | Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies read bio»
FREE | Light hors d'oeuvres will be served
Location & Directions:
MaRS Auditorium, Lower Concourse
101 College Street
Underground parking is available at the MaRS Centre at a cost of $4 per half hour, to a maximum of $18. The MaRS Centre underground lot can be accessed via Elizabeth Street, just south of College Street on the west side of the road. It can also be accessed via University Avenue when driving northbound, just past the Peter Munk Cardiac Centre, south of College Street. Substantial additional parking is available at a host of parking garages and above ground lots within a two-block radius.
- Subway: MaRS offers direct access to the Queen's Park subway station, with connecting service to Go Trains at Union Station.
- Street Car: The College Street streetcar stops at the corner of Elizabeth St & College Street at the north-east corner of the MaRS Centre.
By charter bus
The main Toronto Bus Terminal is located a short five minute walk away south of the MaRS Centre on Elizabeth Street.
From Lester B. Pearson International Airport
- Start going toward the AIRPORT EXIT on TERMINAL ACCESS ROAD – go 0.3 km
- Continue on AEROQUAY CRES – go 0.3 km
- Take left ramp onto ON-409 – go 5.8 km
- ON-409 becomes MACDONALD-CARTIER FWY – go 0.3 km
- MACDONALD-CARTIER FWY becomes ON-401 – go 8.5 km
- Take ramp onto WILLIAM R ALLEN RD – go 4.0 km
- Take left ramp toward EGLINTON AVE W – go < 0.1 km
- Turn left on EGLINTON AVE W – go 1.0 km
- Turn right on BATHURST ST – go 5.1 km
- Turn left on COLLEGE ST – go 1.6 km
- Arrive at 101 COLLEGE ST, TORONTO
From Union Station, Toronto:
- Start on UNIVERSITY AVE (at FRONT ST W & UNIVERSITY AVE in TORONTO) going toward HEENAN PL (northward) – go 1.1 mi
- Turn right on COLLEGE ST – go 0.1 mi
- Arrive at 101 COLLEGE ST, TORONTO
Johnson & Johnson Participating Representatives' Biographies:
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.
Connect with Kuldeep:
Thomas Luby, Ph.D., Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Tom is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston. He focuses primarily on cardiovascular & metabolic; infectious diseases and Vaccines; and neurobiology.
Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies. In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the BOD at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture.
Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech. He has worked on multiple discovery through Phase II programs in infectious disease, oncology, immunotherapy, and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach.
Tom received his BS in Biology from State University of New York, his Ph.D. in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.
Connect with Tom:
Melinda Richter, Head, Johnson & Johnson Innovation, JLABS
As Head of JLABS, Melinda fosters Johnson & Johnson's external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company.
Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.
Connect with Melinda:
Bruce R. Rosengard, M.D., FRCS | Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. Bruce and his team will identify emerging surgical trends and novel technology platforms with the goal of bringing innovative device solutions in the surgical and interventional spaces into the Medical Devices portfolio.
A cardiothoracic surgeon and NIH-funded scientist, Dr. Rosengard, previously served as Vice President, New Business Ventures for The Medicines Company, where he played a pivotal role in several major acquisitions that have expanded the Medicines Company’s Surgical and Perioperative Care franchise. Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the faculty of Harvard Medical School. In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation immunology. Prior to this, Dr. Rosengard was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered “beating heart” transplantation. Bruce started his career at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure.
Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.